抗体药物偶联物（ADC）是对肿瘤细胞发挥特异性细胞毒性的新型药物。中国于 2023 年 5 月批准了 T-Dxd，其推出改变了国家的临床实践。尽管全球有超过700种ADC正在研究中，但抗体工程、药物发现、安全管理、耐药性、药物选择和测序方面仍然存在的挑战阻碍了ADC的进一步推广和应用。中国的专家们讨论了2022年以来与临床实践相关的几个关键问题。在这里，作者对ADC进行了回顾，然后讨论了中国探索的几种ADC。这项研究提出了几种解决方案和策略，以最大限度地发挥 ADC 为乳腺癌患者提供的潜在益处。© 2023 美国癌症协会。

Antibody drug conjugates (ADCs) are novel drugs that exert specific cytotoxicity against tumor cells. China approved T-Dxd in May 2023, and their introduction has changed the nation's clinical practice. Although more than 700 ADCs are being investigated worldwide, the challenges that remain in antibody engineering, drug discovery, safety management, resistance, drug selection, and sequencing hinder the further promotion and application of ADCs. Experts in China have discussed the several critical concerns related to clinical practice since 2022. Here, the authors conducted a review of ADCs and then discussed several ADCs explored in China. This study proposes several solutions and strategies to maximize the potential benefit that ADCs can provide to patients with breast cancer.© 2023 American Cancer Society.